Díaz-Lobato Salvador, Alises Sagrario Mayoralas, Rodríguez Esteban Pérez
Pneumological Department, Hospital Ramón y Cajal, Madrid, Spain.
Int J Chron Obstruct Pulmon Dis. 2006;1(2):129-35. doi: 10.2147/copd.2006.1.2.129.
Noninvasive ventilation (NIV) has been one of the major advances in respiratory medicine in the last decade. NIV improves quality of life, prolongs survival, and improves gas exchange and sleep quality in restrictive patients, but evidence available now does not allow us to establish clear criteria for prescribing NIV in patients with chronic respiratory failure due to COPD. On the basis of the available studies, NIV should not be used as a treatment of choice for all patients with COPD, even when disease is severe. However, there is more evidence that NIV has an important effect in these patients. In fact, a selected group of patients may well benefit from domiciliary mechanical ventilation, and we need to be able to identify who they are. Moreover, NIV can be a new strategy to improve exercise tolerance in COPD patients.
无创通气(NIV)是过去十年呼吸医学领域的重大进展之一。无创通气可改善生活质量、延长生存期,并改善限制性疾病患者的气体交换和睡眠质量,但目前的证据尚无法让我们为慢性阻塞性肺疾病(COPD)所致慢性呼吸衰竭患者制定明确的无创通气处方标准。基于现有研究,无创通气不应作为所有COPD患者的首选治疗方法,即使疾病严重时也不行。然而,有更多证据表明无创通气对这些患者有重要作用。事实上,一部分特定患者可能会从家庭机械通气中获益,我们需要能够识别出这些患者。此外,无创通气可能是提高COPD患者运动耐力的一种新策略。